Gastric Adenocarcinoma, Surgery, Laparoscopic
Conditions
Brief summary
The Benchmark-MISGC study was a large-scale retrospective observational study launched by the China Gastric Cancer Surgical Union, aiming to establish the benchmarks of the short- and long-term outcomes for gastric cancer patients who underwent minimal invasive gastrectomy.
Interventions
OTHERNone-placebo
None, observational study
Sponsors
Fujian Medical University
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
1. Patients with postoperative histologically confirmed gastric adenocarcinoma at stages T1-4a, N0/+, M0; 2. underwent robotic or laparoscopic gastrectomies with curative intent
Exclusion criteria
1. ASA class \> 3; 2. remnant gastric cancer; 3. concurrent/previous malignant disease; 4. Distant metastasis; 5. Palliative resection; 6. Abodominal exploration.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Benchmark values of overall complication | 30 days | Median values of continuous variables and the proportions of categorical variables were calculated per participating centre. Benchmark values, indicating 'best achievable' results for each outcome indicator, were set at the 25th percentile for positive parameters (for example lymph node yield) or the 75th percentile for negative parameters (for example complications) of the centers' median values. Postoperative complications were evaluated within 30 days following surgery. These postoperative complications include gastrointestinal-related complications, incision-related complications, respiratory complications, cardiovascular and cerebrovascular complications, urinary system complications, infection complications, embolism complications, and other complications. The grading of postoperative complications adopts the Clavien-Dindo classification. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Benchmark values of Disease-specific survival (DSS) | 1-year, 2-year, and 3-year | Benchmark values of 1-year, 2-year and 3-year DSS. DSS was defined as the time from surgery to death from gastric cancer, or last follow-up. |
| benchmark value of the number of harvest lymph nodes | 1 month | the number of harvest lymph nodes |
| Benchmark values of Mortality rates | 30 days | Patient died during hospitalization. |
| Benchmark values of Overall survival (OS) | 1-year, 2-year and 3-year | Benchmark values of 1-year, 2-year and 3-year OS. OS was defined as the time from surgery to death from any cause or last follow-up. |
| Benchmark values of Intraoperative blood loss | 1 day | Intraoperative blood loss |
| Benchmark values of operation time | 1 day | From skin incision to skin closure |
| Benchmark values of textbook Outcome | 30 days | Textbook outcome (TO) was defined based on review of existing TO metrics in the literature including outcomes such as complete-potentially curative status, no intraoperative complications, no eventful postoperative complications (Clavien-Dindo grade III or higher), 15 lymph nodes(LNs) examined, hospital stay \< 21days, no reintervention (surgical, endoscopic or radiological) within 30 days after surgery, no readmission to the intensive care unit (ICU) within 30 days after surgery, no postoperative mortality within 30 days after surgery, and no hospital readmission within 30 days after discharge. When all nine desired health outcomes were realized, TO was achieved. |
| Benchmark values of the incidence of intraoperative complications | 1 days | Intraoperative complications were defined as bleeding due to named vessel injury, injury to visceral organs, mechanical factor-related problems, cardiopulmonary dysfunction due to hypercapnia, and other complications |
Countries
China
Outcome results
None listed